"Ramipril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.
Concept/Terms
Vesdil- Vesdil
- AstraZeneca Brand of Ramipril
- Promed Brand of Ramipril
Carasel- Carasel
- Almirall Brand of Ramipril
Triatec- Triatec
- Altace
- Delix
- Ramace
- Monarch Brand of Ramipril
- Zabien
- Aventis Brand of Ramipril
- Hoechst Brand of Ramipril
- Aventis Pharma Brand of Ramipril
- Astra Brand of Ramipril
- Acovil
- Tritace
Below are MeSH descriptors whose meaning is more general than "Ramipril".
Below are MeSH descriptors whose meaning is more specific than "Ramipril".
This graph shows the total number of publications written about "Ramipril" by people in Harvard Catalyst Profiles by year, and whether "Ramipril" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 1 | 2 |
1996 | 1 | 0 | 1 |
1997 | 3 | 0 | 3 |
2001 | 1 | 2 | 3 |
2002 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2006 | 1 | 0 | 1 |
2007 | 2 | 0 | 2 |
2009 | 1 | 1 | 2 |
2012 | 0 | 1 | 1 |
2018 | 2 | 0 | 2 |
2019 | 0 | 2 | 2 |
2021 | 3 | 0 | 3 |
2022 | 0 | 4 | 4 |
2023 | 1 | 4 | 5 |
2024 | 0 | 1 | 1 |
Below are the most recent publications written about "Ramipril" by people in Profiles.
-
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI. J Am Coll Cardiol. 2024 Mar 05; 83(9):904-914.
-
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial. Eur J Heart Fail. 2024 Jan; 26(1):130-139.
-
Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MI. J Am Heart Assoc. 2023 09 05; 12(17):e028942.
-
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy. Biochem Pharmacol. 2023 09; 215:115735.
-
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circ Heart Fail. 2023 05; 16(5):e010259.
-
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study. Am J Cardiovasc Drugs. 2023 Mar; 23(2):207-217.
-
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation. 2022 Dec 06; 146(23):1749-1757.
-
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. Eur J Heart Fail. 2022 Oct; 24(10):1918-1927.
-
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Circulation. 2022 10 04; 146(14):1067-1081.
-
Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 09 15; 387(11):967-977.